Discovery process for antibody-based therapeutics

Development of Antibody-Based Therapeutics: Translational Considerations

Volumn , Issue , 2013, Pages 9-32

  Shih, Heather H ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930144728     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-5955-3_2     Document Type: Chapter

References (40)

1. Azinovic I, DeNardo GL, Lamborn KR, Mirick G, Goldstein D, Bradt BM, DeNardo SJ (2006) Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother 55:1451-1458
2. Baker MP, Jones TD (2007) Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Dev 10:219-227
3. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K et al (2003) Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 100:2023-2028
4. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K et al (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916-919
5. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B (2007) Immunoge-nicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 27:269-274
6. Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31:175-193
7. Coenen MJ, Toonen EJ, Scheffer H, Radstake TR, Barrera P, Franke B (2007) Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics 8:761-773
8. Cohen J, Carlet J (1996) INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 24:1431-1440
9. Daugherty AL, Mrsny RJ (2010) Formulation and delivery issues for monoclonal antibody therapeutics. Biotechnology: Pharmaceutical aspects (Current trends in monoclonal antibody development and manufacturing), vol 11. Springer, New York, pp 103-129
10. De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, Scott DW, Martin W (2008) Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 112:3303-3311
11. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850-8855
12. Descotes J (2009) Immunotoxicity of monoclonal antibodies. MAbs 1:104-111
13. Easthope S, Jarvis B (2001) Omalizumab. Drugs 61:253-260 discussion 261
14. Genazzani AA, Biggio G, Caputi AP, Del Tacca M, Drago F, Fantozzi R, Canonico PL (2007) Biosimilar drugs: concerns and opportunities. Biodrugs 21:351-356
15. Gilles JG, Vanzieleghem B, Saint-Remy JM (2000) Factor VIII Inhibitors. Natural autoantibodies and anti-idiotypes. Semin Thromb Hemost 26:151-155
16. Imai K, Takaoka A (2006) Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6:714-727
17. Jahn EM, Schneider CK (2009) How to systematically evaluate immunogenicity of therapeutic proteins-regulatory considerations. N Biotechnol 25:280-286
18. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX (2010) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128:347-356
19. Kerchner GA, Boxer AL (2010) Bapineuzumab. Expert Opin Biol Ther 10:1121-1130
20. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497
21. Lichtlen P, Mohajeri MH (2008) Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem 104:859-874
22. Maggi E, Vultaggio A, Matucci A (2011) Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 7:55-63
23. Morgan D (2011) Immunotherapy for Alzheimer's disease. J Int Med 269:54-63
24. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767-774
25. Owyang AM, Issafras H, Corbin J, Ahluwalia K, Larsen P, Pongo E, Handa M, Horwitz AH, Roell MK, Haak-Frendscho M, Masat L (2011) XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1beta-mediated diseases. MAbs 3:49-60
26. Pan W, Solomon B, Maness LM, Kastin AJ (2002) Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide. Exp Biol Med (Maywood) 227:609-615
27. Reichert JM (2011) Antibody-based therapeutics to watch in 2011. MAbs 3:76-99
28. Schellekens H (2005) Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 18:473-480
29. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177
30. Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3:75-80
31. Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB (2010) Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33:67-73
32. Stebbings R, Poole S, Thorpe R (2009) Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol 20:673-677
33. Steinberger P, Sutton JK, Rader C, Elia M, Barbas CF 3rd (2000) Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. J Biol Chem 275:36073-36078
34. Strohl WR (2009) Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 20:685-691
35. Tabrizi MA, Bornstein GG, Klakamp SL, Drake A, Knight R, Roskos L (2009) Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today 14:298-305
36. Tsurushita N, Park M, Pakabunto K, Ong K, Avdalovic A, Fu H, Jia A, Vasquez M, Kumar S (2004) Humanization of a chicken anti-IL-12 monoclonal antibody. J Immunol Methods 295:9-19
37. Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K (2009) General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 284:3273-3284
38. Wang W, Singh S, Zeng DL, King K, Nema S (2007) Antibody structure, instability, and formulation. J Pharm Sci 96:1-26
39. Wong D, Joussen AM (2010) The safety of using anti-VEGF: is there strength in numbers? Graefes Arch Clin Exp Ophthalmol 249:161-162
40. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA (2007) Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 368:652-665